LORUS CONTINUES WITH PRECLINICAL SMALL MOLECULE PROGRAM

Lorus Therapeutics announced the continued success in the development of its small molecule anticancer program with the selection of a sub-class of lead molecules from its small molecule program. Two molecules from this sub-class, ML-133 and LT-253, have been chosen as lead candidates for further development as novel anticancer drugs, based on the results of preclinical studies.

ML-133 and LT-253 are part of a group of novel low molecular weight compounds that shows significant antiproliferative activity against many human cancer cell lines. In the in vitro anticancer screening program of the U.S. National Cancer Institute, which includes 60 human cancer cell lines representing nine cancer types, ML-133 exhibited potent activity against colon carcinoma, leukemia, non-small cell lung cancer and prostate cancer cell lines.